Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Wideacademy Restructuring

30 Oct 2018 07:00

RNS Number : 5970F
WideCells Group PLC
30 October 2018
 

30 October 2018

WideCells Group PLC ('WideCells Group' or 'the Group')

 

Board Restructuring and Cost Cutting

 

WideCells Group PLC, the healthcare services group focused on providing stem cell services and insurance for stem cell treatment, has undertaken further corporate restructuring and cost cutting measures to rationalise its Board and to refocus on its core operational divisions.

 

As part of this restructuring, Alan Greenberg has resigned from his positions as a Director of the Board and Chief Business Development Officer and Senior Vice President of Wideacademy.

 

In addition, the Company has closed Wideacademy's London office and has brought the division into the Manchester head office, thereby making annualised savings of approximately £400,000 pa.

 

Wideacademy will continue to use its current collaborations with the education and medical sectors, and will harness Professor Peter Holland's knowledge in stem cell education and training to bolster the Group's stem cell storage and insurance sales.

 

The Group's CEO, João Andrade, said, "I'd like to thank Alan Greenberg for his dedication to WideCells and I wish him all the best for the future. The streamlined Board and Wideacademy is now fully focused on increasing sales at our two core divisions - CellPlan, the world's first stem cell healthcare insurance plan; and WideCells, focused on stem cell storage and, research, in order to generate value for our shareholders."

 

**ENDS**

 

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 

WideCells Group

CEO - João Andrade

Tel: +44 (0)161 920 7953

Shard Capital Partners LLP

Broker - Damon Heath & Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR - Isabel de Salis & Priit Piip

Tel: +44 (0) 20 7236 1177

 

Notes to Editors

 

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments both accessible and affordable. This is delivered through three divisions:

· CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

· WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

· Wideacademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

 

Stem Cell Fast Facts:

· Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families, because it is simple, safe and painless to collect, relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.

· Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

· 82 illnesses can currently be treated using stem cell procedures.

· Despite initial collection and storage often costing no more than a few £thousands, actual treatment can cost in the £hundreds of thousands - before the development of an insurance product such as CellPlan, the treatment remained largely available only to Higher Net Worth individuals.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOADXBDGCGDBGIC
Date   Source Headline
30th Nov 202211:15 amRNSConversion of Securities
1st Nov 20224:50 pmRNSSubscription of convertible notes
22nd Sep 20225:59 pmRNSResults of Creditors and General Meetings
30th Aug 20226:19 pmRNSSettlement and CVA
23rd Aug 20224:57 pmRNSRetraction of claims
8th Jun 20226:05 pmRNSAdministration & proposed CVA update
8th Dec 20216:21 pmRNSResults of General Meeting
26th Nov 202110:05 amRNSAdjournment to the GM
19th Nov 202111:25 amRNSAdjournment to the GM - Replacement
18th Nov 20214:00 pmRNSAdjournment to the GM
15th Nov 20214:54 pmRNSAdjournment of General Meeting
7th Oct 202110:33 amRNSGeneral Meeting – Further adjournment
25th Aug 20212:44 pmRNSNOTICE OF APPROVAL OF ADMINISTRATORS' PROPOSALS
12th Aug 20211:22 pmRNSGM update and adjournment notice
13th Jul 20216:38 pmRNSGM update and adjournment notice
1st Jul 20214:48 pmRNSGM update and adjournment notice
16th Jun 20214:56 pmRNSAnnouncement of resignation of directorship
15th Jun 20214:27 pmRNSUpdate on General Meeting
7th Jun 20217:30 amRNSSuspension - Iconic Labs Plc
4th Jun 20216:39 pmRNSAppointment of Administrators
1st Jun 20219:05 amRNSSecond Price Monitoring Extn
1st Jun 20219:00 amRNSPrice Monitoring Extension
26th May 20214:55 pmRNSDirectorate Change
24th May 20212:06 pmRNSSecond Price Monitoring Extn
24th May 20212:00 pmRNSPrice Monitoring Extension
24th May 202111:05 amRNSSecond Price Monitoring Extn
24th May 202111:00 amRNSPrice Monitoring Extension
24th May 20219:36 amRNSDirectorate Change
24th May 20219:05 amRNSSecond Price Monitoring Extn
24th May 20219:00 amRNSPrice Monitoring Extension
21st May 20217:00 amRNSNotice of GM
20th May 202111:05 amRNSSecond Price Monitoring Extn
20th May 202111:00 amRNSPrice Monitoring Extension
19th May 20214:00 pmRNSDirectorate Change
10th May 202111:05 amRNSSecond Price Monitoring Extn
10th May 202111:00 amRNSPrice Monitoring Extension
10th May 20219:05 amRNSSecond Price Monitoring Extn
10th May 20219:00 amRNSPrice Monitoring Extension
10th May 20218:12 amRNSLetter of Intent Signed : Sting Industries
4th May 20214:41 pmRNSSecond Price Monitoring Extn
4th May 20214:36 pmRNSPrice Monitoring Extension
4th May 20212:06 pmRNSSecond Price Monitoring Extn
4th May 20212:01 pmRNSPrice Monitoring Extension
30th Apr 20214:41 pmRNSSecond Price Monitoring Extn
30th Apr 20214:35 pmRNSPrice Monitoring Extension
30th Apr 20212:17 pmRNSHalf-year Report
29th Apr 20217:52 amRNSDirectorate Change
23rd Apr 202111:05 amRNSSecond Price Monitoring Extn
23rd Apr 202111:00 amRNSPrice Monitoring Extension
21st Apr 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.